Reddy Anupama, Zhang Jenny, Davis Nicholas S, Moffitt Andrea B, Love Cassandra L, Waldrop Alexander, Leppa Sirpa, Pasanen Annika, Meriranta Leo, Karjalainen-Lindsberg Marja-Liisa, Nørgaard Peter, Pedersen Mette, Gang Anne O, Høgdall Estrid, Heavican Tayla B, Lone Waseem, Iqbal Javeed, Qin Qiu, Li Guojie, Kim So Young, Healy Jane, Richards Kristy L, Fedoriw Yuri, Bernal-Mizrachi Leon, Koff Jean L, Staton Ashley D, Flowers Christopher R, Paltiel Ora, Goldschmidt Neta, Calaminici Maria, Clear Andrew, Gribben John, Nguyen Evelyn, Czader Magdalena B, Ondrejka Sarah L, Collie Angela, Hsi Eric D, Tse Eric, Au-Yeung Rex K H, Kwong Yok-Lam, Srivastava Gopesh, Choi William W L, Evens Andrew M, Pilichowska Monika, Sengar Manju, Reddy Nishitha, Li Shaoying, Chadburn Amy, Gordon Leo I, Jaffe Elaine S, Levy Shawn, Rempel Rachel, Tzeng Tiffany, Happ Lanie E, Dave Tushar, Rajagopalan Deepthi, Datta Jyotishka, Dunson David B, Dave Sandeep S
Duke Cancer Institute and Center for Genomic and Computational Biology, Duke University, Durham, NC, USA; Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Duke Cancer Institute and Center for Genomic and Computational Biology, Duke University, Durham, NC, USA.
Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity poses a major barrier to understanding the genetic basis of the disease and its response to therapy. Here, we performed an integrative analysis of whole-exome sequencing and transcriptome sequencing in a cohort of 1,001 DLBCL patients to comprehensively define the landscape of 150 genetic drivers of the disease. We characterized the functional impact of these genes using an unbiased CRISPR screen of DLBCL cell lines to define oncogenes that promote cell growth. A prognostic model comprising these genetic alterations outperformed current established methods: cell of origin, the International Prognostic Index comprising clinical variables, and dual MYC and BCL2 expression. These results comprehensively define the genetic drivers and their functional roles in DLBCL to identify new therapeutic opportunities in the disease.
弥漫性大B细胞淋巴瘤(DLBCL)是最常见的血癌形式,其特征是具有显著程度的遗传和临床异质性。这种异质性对理解该疾病的遗传基础及其对治疗的反应构成了主要障碍。在此,我们对1001例DLBCL患者进行了全外显子组测序和转录组测序的综合分析,以全面界定该疾病150个遗传驱动因素的情况。我们通过对DLBCL细胞系进行无偏差的CRISPR筛选来表征这些基因的功能影响,以确定促进细胞生长的癌基因。包含这些遗传改变的预后模型优于目前已确立的方法:细胞起源、包含临床变量的国际预后指数以及MYC和BCL2双表达。这些结果全面界定了DLBCL中的遗传驱动因素及其功能作用,以识别该疾病的新治疗机会。